# In May 2019, Ashland launched the Aquaflow NMS 460E rheology modifier, a nonionic synthetic associative thickener.
# In May 2019, Colorcon launched STARTAB, a new starch tableting excipient designed specifically for the direct compression process.
Overview of This Study:
This study involved four major activities in estimating the current size of the pharmaceutical excipients market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.
The global pharmaceutical excipients market is highly competitive. The prominent players operating in this market include Ashland Global Holdings, Inc (US), International Flavors & Fragrances, Inc. (US), BASF SE (Germany), Evonik Industries AG (Germany), Roquette Frères (France), Associated British Foods plc (UK), Archer Daniels Midland Company (US), Lubrizol Corporation (US), Innophos Holdings (US), Kerry Group plc (Ireland), Wacker Chemie AG (Germany), Air Liquide (France), Dow Chemicals (US), Colorcon (US), DMV-Fonterra Excipients (Germany), JRS Pharma GmbH (Germany), Meggle GmbH & Co Kg (Germany), Finar Limited (India), Fuji Chemical Industries Co., Ltd (Japan), Merck KGaA (Germany), Captisol (US), Ideal Cures Pvt. Ltd (India), Corel Pharma Chem (India), Biogrund GmbH (Germany), Nitika Pharmaceutical Specialties Pvt. Ltd (India).
Growth Strategies Adopted by Them:
Geographic expansions and collaborations are the key growth strategies undertaken by these companies to maintain their positions in the market.
Download PDF Brochure@
Evonik Industries AG
Evonik serves the health, consumer, and real estate markets globally with a major focus on health, nutrition, and resource efficiency. The company operates in five business segments: Nutrition & Care, Smart Materials, Specialty Additives, Performance Materials, and Technology and Infrastructure. The Nutrition & Care segment deals with pharmaceutical excipients by offering polymers and excipients for the controlled release of pharmaceuticals. These business segments also deal with active pharmaceutical ingredients and nutritional materials.
Evonik Industries has a vast polymer product portfolio in the pharmaceutical excipients market. The companys wide geographical presence with its production facilities, subsidiaries, and distribution channels enables it to reach out to a large customer base. Evonik mainly focuses on expanding its product portfolio in other industries to meet customer expectations. Evonik has 174 subsidiaries and is present in more than 100 countries across the globe, with production sites in 25 countries
International Flavors & Fragrances Inc.
International Flavors & Fragrances Inc. manufactures food, beverage, health & biosciences, scent & pharma solutions, and adjacent complementary products, including cosmetic active & natural health ingredients. In February 2021, International Flavors & Fragrances Inc (IFF) merged with and into Nutrition & Biosciences, Inc., a subsidiary of DuPont holding its Nutrition and Biosciences business. The company operates through four business segmentsNourish, Health & Biosciences, Scent, and Pharma Solutions. The company offers pharmaceutical excipients through its Pharma Solutions segment. The company has a global presence and operates in North America, the Asia Pacific, Europe, Latin America, and the Middle East.
Ashland Global Holdings Inc
Ashland has a diversified product portfolio, which comprises a wide range of tablet binding, tablet disintegration, tablet film coating, solubilizers, and rheology modifier excipients. Ashlands leading position in the market is attributed to its R&D activities, strong manufacturing capabilities, and wide distribution footprint, enabling it to serve customers in more than 100 countries. The company is focusing on expanding its product portfolio in the pharmaceutical excipients market to meet the rising consumer demand.
Ashland incessantly focuses on developing the specialty chemicals business by investing in product discovery. The companys strategic priority is to leverage its position in the market by focusing on product launches through customer-focused innovation, enabling it to target a larger customer base and diversify its revenue streams.
Request Sample Pages@
Revenue Growth Expectations:
The pharmaceutical excipients market is projected to reach USD 11.5 billion by 2027 from USD 8.6 billion in 2022, at a CAGR of 5.9% during the forecast period.
Global Industry Growth Dynamics:
The rapidly growing pharmaceuticals market coupled with rise in generics production is driving the market growth for pharmaceutical excipients. However, the increasing regulatory stringency regarding the approval of drugs and excipients, along with the cost and time-intensive drug development process, are expected to restrain the growth of this market.